CORPORATE ACCESS

Study by LUMC Shows Overall Survival of 20.3 Months in Patients with Ocular Melanoma Liver MetastasesNEW YORK, April 16, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

NEW YORK, Feb. 28, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, highlights the experiences of patients with ocular melanoma as part of Rare Disease Day®-a...

Discussions Underway With Potential Commercialization Partners NEW YORK, Feb. 11, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has...

NEW YORK, Feb. 08, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a prospective phase 2 study conducted in the Netherlands of the use...

7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK, Dec. 26, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology...

Trial Continues on Scheduled Path with Expected Completion of Enrollment by June 2019 NEW YORK, Dec. 18, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...

NEW YORK, Nov. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended September 30, 2018. Highlights from the third quarter...

The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. 18, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional...

Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 -- In a release issued under the same headline earlier today by Delcath Systems, Inc. (OTCQB: DCTH), please note the first sentence of the first paragraph should read:...

Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces the...

PHP Therapy in ICC Treatment Shows Promise in Retrospective Analysis NEW YORK, Oct. 04, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results of a...

NEW YORK, Sept. 27, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announces the closing of the subscription period of its previously announced rights offering....

Positive Results Observed in Study Endpoints Comparable to Endpoints in Delcath Registration Trial NEW YORK, Sept. 26, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

NEW YORK, Sept. 24, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that data from a study conducted in Germany of the use of the Delcath Hepatic...

NEW YORK, Sept. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the expiration on Wednesday September 26, 2018. The subscription rights...

NEW YORK, Sept. 04, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the result of a multicenter analysis of outcomes in patients with intrahepatic...

NEW YORK, Aug. 28, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has completed the initial rights offering period and will be extending for an...

NEW YORK, Aug. 27, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a study conducted in Germany of the use of the Delcath Hepatic...

Trial Continues on Scheduled Path with Expected Completion of Enrollment by June 2019 NEW YORK, Aug. 23, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...

Reminder of August 27, 2018 Deadline NEW YORK, Aug. 22, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the initial expiration, on Monday...

NEW YORK, Aug. 21, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the first patient has been enrolled under the amended protocol for its...

Stanford University Medical Center First Location to Begin Enrollment Under Single Arm Protocol NEW YORK, Aug. 20, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...

NEW YORK, Aug. 17, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief...

NEW YORK, Aug. 15, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended June 30, 2018. Highlights from the second quarter of...

NEW YORK, Aug. 06, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces the subscription period for its previously announced rights offering begins on Tuesday,...

The Company's Directors and Officers Indicate Intent to Participate in the Rights Offering Once Effective NEW YORK, July 31, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver...

Revision to Nonrandomized (Single Arm) Study Reduces Trial Size Enrollment Requirement Enrollment Anticipated to be Completed by First Half 2019 NEW YORK, July 27, 2018 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment...

NEW YORK, July 16, 2018 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it has filed a registration statement on Form S-1 with the SEC for a rights...

NEW YORK, July 09, 2018 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that physicians at Leiden University Medical Center (LUMC) in the Netherlands, led by...

NEW YORK, May 29, 2018 -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at...

NEW YORK, May 22, 2018 -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to sponsor A Cure In Sight and its first annual Looking for a Cure 5K charity event. A Cure in...

NEW YORK, May 16, 2018 -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the German Guidelines Program in Oncology (GGPO) has included treatment with Delcath's...

NEW YORK, May 14, 2018 -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company's PHP Therapy was featured in a Video Learning Session presented at the...

NEW YORK, May 10, 2018 -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended March 31, 2018. Highlights from the first quarter of...

Duke Medical Center Opens for Patient Enrollment NEW YORK, May 07, 2018 -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company has initiated its pivotal...

NEW YORK, May 04, 2018 -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath,...

NEW YORK, Feb. 01, 2018 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has satisfied all of its obligations under the privately placed senior secured...

NEW YORK, Jan. 10, 2018 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has concluded a modification agreement with the U.S. Food and Drug Administration...

NEW YORK, Jan. 09, 2018 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that results of a multi-center retrospective analysis of Delcath's PHP® Therapy have been...

NEW YORK, Dec. 29, 2017 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces on December 28, 2017, it entered into exchange agreements (collectively, "Exchange...

NEW YORK, Dec. 19, 2017 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial...

NEW YORK, Dec. 05, 2017 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that results of a multi-center retrospective analysis of Delcath's PHP® Therapy have been...

NEW YORK, Sept. 22, 2017 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer, has issued...

NEW YORK, Sept. 19, 2017 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the results of a single institution study were presented at the Cardiology and...

NEW YORK, Sept. 14, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that after conversations with both Nasdaq and OTC Markets, the Company is able to effect the...

Company to Ensure Orderly Transition from NASDAQ to OTC Market NEW YORK, Sept. 13, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that its Board of Directors...

NEW YORK, Sept. 01, 2017 -- Delcath Systems, Inc. (Nasdaq:DCTH) (the "Company"), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive...

NEW YORK, Aug. 29, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, congratulates the team at the Medical University of Hannover Hospital on their performance of the...

Agreement Contingent upon Shareholder Vote in Favor of the Proposed Reverse Stock Split Voting Deadline Extended to September 7, 2017 NEW YORK, Aug. 28, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary...

NEW YORK, Aug. 22, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company") announced today that the deadline for its current Consent Solicitation (the "Consent Solicitation"), currently set to expire at 5:00 p.m. Eastern Time, on August 28, 2017, has been extended...